Overview

HYPAZ: Hypertension Induced by Pazopanib

Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Pazopanib is a new cancer drug that works by limiting the growth of new blood vessels in tumours. About half of patients who take pazopanib develop high blood pressure (hypertension). This side effect can make patients have to reduce or stop their cancer treatment, and can cause other health problems. The aim of this study is to find out exactly how the drug causes high blood pressure.
Phase:
Phase 2
Details
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Collaborators:
GlaxoSmithKline
University of Cambridge